Bibliografía científicaBibliografía científica

En esta sección encontrará una selección de las publicaciones científicas sobre los Trastornos del Movimiento para los 11 diferentes tipos establecidos por la International Parkinson & Movement Disorder Society. Se han seleccionado sólo aquellas publicaciones que presenten el término de búsqueda en el título (inglés).

Los artículos presentados incluyen aquellos publicados desde enero de 2010. El listado de publicaciones de actualizará mensualmente. Si lo desea, puede recibir una alerta de la actualización por correo electrónico. Para ello ha de registrarse.

Enfermedad de Parkinson y Parkinsonismo Parkinson’s disease & Parkinsonism 2030 artículos Viendo del 1 al 40 de 2030 artículos

Discovery of a novel metabotropic glutamate receptor 4 (mGlu(4)) positive allosteric modulator (PAM) extended probe: Characterization of ML292, a potent and selective mGlu(4) PAM which produces efficacy alone or in combination with L-DOPA in preclinical rodent models of Parkinson's disease.NUEVO

Engers DW, Jones CK, Bubser M, Thompson AD, Blobaum AL, Sheffler DJ, Zamorano R, Carrington SJS, Bridges TM, Morrison RD, Daniels JS, Conn PJ, Lindsley CW, Niswender CM, Hopkins CR.
2012 Apr 2 [updated 2013 Feb 25]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.

Costs of Parkinson's disease in eastern Europe: a Czech cohort study.NUEVO

Winter Y, von Campenhausen S, Brozova H, Skoupa J, Reese JP, Bötzel K, Eggert K, Oertel WH, Dodel R, Ruzicka E.
Parkinsonism Relat Disord. 2010 Jan;16(1):51-6. doi: 10.1016/j.parkreldis.2009.07.005.

Behavioural assessment of dysexecutive syndrome in Parkinson's disease without dementia: a comparison with other clinical executive tasks.NUEVO

Perfetti B, Varanese S, Mercuri P, Mancino E, Saggino A, Onofrj M.
Parkinsonism Relat Disord. 2010 Jan;16(1):46-50. doi: 10.1016/j.parkreldis.2009.07.011.

Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease.NUEVO

Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C.
J Neurol. 2010 Jan;257(1):72-8. doi: 10.1007/s00415-009-5267-3.

Validity of a Brazilian version of the Zung self-rating depression scale for screening of depression in patients with Parkinson's disease.NUEVO

Chagas MH, Tumas V, Loureiro SR, Hallak JE, Trzesniak C, de Sousa JP, Rodrigues GG, Santos Filho A, Crippa JA.
Parkinsonism Relat Disord. 2010 Jan;16(1):42-5. doi: 10.1016/j.parkreldis.2009.07.010.

The neural circuitry of executive functions in healthy subjects and Parkinson's disease.NUEVO

Leh SE, Petrides M, Strafella AP.
Neuropsychopharmacology. 2010 Jan;35(1):70-85. doi: 10.1038/npp.2009.88. Review.

Tremor amplitude and tremor frequency variability in Parkinson's disease is dependent on activity and synchronisation of central oscillators in basal ganglia.NUEVO

Bartolić A, Pirtosek Z, Rozman J, Ribaric S.
Med Hypotheses. 2010 Feb;74(2):362-5. doi: 10.1016/j.mehy.2009.06.057.

Sexual and relationship satisfaction among persons with young-onset Parkinson's disease.NUEVO

Wielinski CL, Varpness SC, Erickson-Davis C, Paraschos AJ, Parashos SA.
J Sex Med. 2010 Apr;7(4 Pt 1):1438-44. doi: 10.1111/j.1743-6109.2009.01408.x.

Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation.NUEVO

Ma L, Cao TT, Kandpal G, Warren L, Fred Hess J, Seabrook GR, Ray WJ.
Neurochem Res. 2010 Jan;35(1):130-42. doi: 10.1007/s11064-009-0038-1.

Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.NUEVO

Constantinescu R, Rosengren L, Johnels B, Zetterberg H, Holmberg B.
Parkinsonism Relat Disord. 2010 Feb;16(2):142-5. doi: 10.1016/j.parkreldis.2009.07.007.

Impact of pre-morbid depression on health-related quality of life in non-demented Parkinson's disease patients.NUEVO

Klepac N, Hajnsek S, Trkulja V.
Parkinsonism Relat Disord. 2010 Jan;16(1):21-7. doi: 10.1016/j.parkreldis.2009.07.003.

Risk of stroke in patients with idiopathic Parkinson disease.NUEVO

Becker C, Jick SS, Meier CR.
Parkinsonism Relat Disord. 2010 Jan;16(1):31-5. doi: 10.1016/j.parkreldis.2009.06.005.

A computerized survey of pain in Parkinson's disease patients: A pilot feasibility study.NUEVO

Page DB, Weaver F, Wilkie DJ, Simuni T.
Parkinsonism Relat Disord. 2010 Feb;16(2):139-41. doi: 10.1016/j.parkreldis.2009.07.001.

Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.NUEVO

Narayana S, Fox PT, Zhang W, Franklin C, Robin DA, Vogel D, Ramig LO.
Hum Brain Mapp. 2010 Feb;31(2):222-36. doi: 10.1002/hbm.20859.

Single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57BL/6 mice models early preclinical phase of Parkinson's disease.NUEVO

Prediger RD, Aguiar AS Jr, Rojas-Mayorquin AE, Figueiredo CP, Matheus FC, Ginestet L, Chevarin C, Bel ED, Mongeau R, Hamon M, Lanfumey L, Raisman-Vozari R.
Neurotox Res. 2010 Feb;17(2):114-29. doi: 10.1007/s12640-009-9087-0.

Is obstructive sleep apnea a problem in Parkinson's disease?NUEVO

Cochen De Cock V, Abouda M, Leu S, Oudiette D, Roze E, Vidailhet M, Similowski T, Arnulf I.
Sleep Med. 2010 Mar;11(3):247-52. doi: 10.1016/j.sleep.2009.05.008.

Low frequency of the PARK2 gene mutations in Polish patients with the early-onset form of Parkinson disease.NUEVO

Koziorowski D, Hoffman-Zacharska D, Sławek J, Szirkowiec W, Janik P, Bal J, Friedman A.
Parkinsonism Relat Disord. 2010 Feb;16(2):136-8. doi: 10.1016/j.parkreldis.2009.06.010.

Dietary glycemic index is inversely associated with the risk of Parkinson's disease: a case-control study in Japan.NUEVO

Murakami K, Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M; Fukuoka Kinki Parkinson's Disease Study Group..
Nutrition. 2010 May;26(5):515-21. doi: 10.1016/j.nut.2009.05.021.

Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.NUEVO

Monti B, Gatta V, Piretti F, Raffaelli SS, Virgili M, Contestabile A.
Neurotox Res. 2010 Feb;17(2):130-41. doi: 10.1007/s12640-009-9090-5.

Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET.NUEVO

Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, Mizusawa H, Ishii K.
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):3-11. doi: 10.1007/s00259-009-1202-1.

Is (123)I-MIBG cardiac scintigraphy a surrogate marker for Parkinson's disease?NUEVO

Fukuyama H.
Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):1-2. doi: 10.1007/s00259-009-1215-9. No abstract available.

The effects of acute tryptophan depletion on mood in patients with Parkinson's disease and the healthy elderly.NUEVO

Mace JL, Porter RJ, Dalrymple-Alford JC, Anderson TJ.
J Psychopharmacol. 2010 Apr;24(4):615-9. doi: 10.1177/0269881109105572.

Segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating.NUEVO

Schüpbach WM, Corvol JC, Czernecki V, Djebara MB, Golmard JL, Agid Y, Hartmann A.
J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):20-5. doi: 10.1136/jnnp.2008.159699.

Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.NUEVO

Devi L, Anandatheerthavarada HK.
Biochim Biophys Acta. 2010 Jan;1802(1):11-9. doi: 10.1016/j.bbadis.2009.07.007. Review.

Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial.NUEVO

Fernandez HH, Greeley DR, Zweig RM, Wojcieszek J, Mori A, Sussman NM; 6002-US-051 Study Group..
Parkinsonism Relat Disord. 2010 Jan;16(1):16-20. doi: 10.1016/j.parkreldis.2009.06.008.

[Gait disorders in Parkinson's disease: and pathophysiological approaches].NUEVO

Moreau C, Cantiniaux S, Delval A, Defebvre L, Azulay JP.
Rev Neurol (Paris). 2010 Feb;166(2):158-67. doi: 10.1016/j.neurol.2009.05.010. Review. French.

Focusing effects of L-dopa in Parkinson's disease.NUEVO

Ng B, Palmer S, Abugharbieh R, McKeown MJ.
Hum Brain Mapp. 2010 Jan;31(1):88-97. doi: 10.1002/hbm.20847.

Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease.NUEVO

Payami H, Kay DM, Zabetian CP, Schellenberg GD, Factor SA, McCulloch CC.
Genet Epidemiol. 2010 Jan;34(1):92-9. doi: 10.1002/gepi.20439.

Pilot study of a three-step diagnostic pathway for young and old patients with Parkinson's disease dementia: screen, test and then diagnose.NUEVO

Robben SH, Sleegers MJ, Dautzenberg PL, van Bergen FS, ter Bruggen JP, Rikkert MG.
Int J Geriatr Psychiatry. 2010 Mar;25(3):258-65. doi: 10.1002/gps.2331.

Dopamine D1 receptor gene expression studies in unilateral 6-hydroxydopamine-lesioned Parkinson's rat: effect of 5-HT, GABA, and bone marrow cell supplementation.NUEVO

Nandhu MS, Fabia ET, Paulose CS.
J Mol Neurosci. 2010 May;41(1):1-11. doi: 10.1007/s12031-009-9213-8.

Independent influences of sex steroids of systemic and central origin in a rat model of Parkinson's disease: A contribution to sex-specific neuroprotection by estrogens.NUEVO

Gillies GE, McArthur S.
Horm Behav. 2010 Jan;57(1):23-34. doi: 10.1016/j.yhbeh.2009.06.002. Review.

Mutations in the Parkinson's disease genes, Leucine Rich Repeat Kinase 2 (LRRK2) and Glucocerebrosidase (GBA), are not associated with essential tremor.NUEVO

Clark LN, Kisselev S, Park N, Ross B, Verbitsky M, Rios E, Alcalay RN, Lee JH, Louis ED.
Parkinsonism Relat Disord. 2010 Feb;16(2):132-5. doi: 10.1016/j.parkreldis.2009.05.008.

Continuous subcutaneous infusion of apomorphine can be used safely in patients with Parkinson's disease and pre-existing visual hallucinations.NUEVO

van Laar T, Postma AG, Drent M.
Parkinsonism Relat Disord. 2010 Jan;16(1):71-2. doi: 10.1016/j.parkreldis.2009.05.006. No abstract available.

In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.NUEVO

Giuffrida A, McMahon LR.
Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):90-103. doi: 10.1016/j.prostaglandins.2009.05.004. Review.

Effects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson's disease.NUEVO

Costa A, Carlesimo GA, Caltagirone C, Mazzone P, Pierantozzi M, Stefani A, Peppe A.
Parkinsonism Relat Disord. 2010 Jan;16(1):64-7. doi: 10.1016/j.parkreldis.2009.05.009.

Long term understanding of study information in research participants with Parkinson's disease.NUEVO

Ravina B, Swearingen C, Elm J, Kamp C, Kieburtz K, Kim SY.
Parkinsonism Relat Disord. 2010 Jan;16(1):60-3. doi: 10.1016/j.parkreldis.2009.05.007.

Is there muscular weakness in Parkinson's disease?NUEVO

Cano-de-la-Cuerda R, Pérez-de-Heredia M, Miangolarra-Page JC, Muñoz-Hellín E, Fernández-de-Las-Peñas C.
Am J Phys Med Rehabil. 2010 Jan;89(1):70-6. doi: 10.1097/PHM.0b013e3181a9ed9b. Review.

[11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease?NUEVO

Bartels AL, Willemsen AT, Doorduin J, de Vries EF, Dierckx RA, Leenders KL.
Parkinsonism Relat Disord. 2010 Jan;16(1):57-9. doi: 10.1016/j.parkreldis.2009.05.005.

Visual-spatial disembedding in Parkinson's disease.NUEVO

Crucian GP, Armaghani S, Armaghani A, Foster PS, Burks DW, Skoblar B, Drago V, Heilman KM.
J Clin Exp Neuropsychol. 2010 Feb;32(2):190-200. doi: 10.1080/13803390902902441.

Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson's disease: large-scale collaborative study.NUEVO

Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Broeckhoven C, Sharma M, Silburn PA, Tan EK, Wirdefeldt K, Ioannidis JP; et al.
Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):220-8. doi: 10.1002/ajmg.b.30980.
Viendo del 1 al 40 de 2030 artículos
Con el aval de:

Sociedad Española de Neurología

Sociedad Española
de Neurología
En colaboración con:


Haga click en el logo para acceder
a información acerca de Zambon
Utilizamos cookies propias y de terceros para identificar la sesión del usuario y mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Si continúa navegando por el sitio web manifiesta consentir su instalación y uso conforme lo anterior. Puede cambiar la configuración y obtener más información aquí.